Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Kregel, Steven, Chen, James L., Tom, Westin, Krishnan, Venkatesh, Kach, Jacob, Brechka, Hannah, Fessenden, Tim B., Isikbay, Masis, Paner, Gladell P., Szmulewitz, Russell Z., Vander Griend, Donald J.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://ncbi.nlm.nih.gov/pubmed/27036029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8456
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares